VanEck Associates’s Arcturus Therapeutics ARCT Stock Holding History

VanEck Associates’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-766	Closed	-$93K	–	702
2014 Q2	$93K	Buy	766 +154	+25%	+$18.6K	﹤0.01%	682
2014 Q1	$78K	Buy	612 +127	+26%	+$18.8K	﹤0.01%	665
2013 Q4	$61K	Buy	+485	New	+$60.9K	﹤0.01%	658

Other funds holding ARCT

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AWMDMG

Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

VanEck Associates's ARCT Position: Q3 2014 in Review

VanEck Associates sold out of Arcturus Therapeutics (ARCT) in Q3 2014, closing a stake of 766 shares — an estimated $93K sold.

VanEck Associates first reported a position in ARCT in Q4 2013 and held it in 3 quarters. The position peaked at $93K in Q2 2014. 38 funds tracked by Wall St. Rank hold ARCT as of Q3 2014.

VanEck Associates reported no remaining Arcturus Therapeutics position as of Q3 2014 after selling out during the quarter.
VanEck Associates sold 766 Arcturus Therapeutics shares in Q3 2014, an estimated $93K.
VanEck Associates first reported a position in Arcturus Therapeutics in Q4 2013 and held it in 3 quarters.
VanEck Associates's Arcturus Therapeutics position peaked at $93K in Q2 2014.
38 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2014.

Based on VanEck Associates's 13F filing for Q3 2014, filed 14 Nov 2014.